Kami J. Maddocks MD
Assistant Professor, Internal Medicine, Ohio State University College of Medicine
Join to View Full Profile
460 W 10th AveColumbus, OH 43210
Phone+1 614-293-8619
Fax+1 614-293-6420
Dr. Maddocks is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Ohio State University HospitalFellowship, Hematology and Medical Oncology, 2008 - 2011
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2005 - 2008
University of South Dakota, Sanford School of MedicineClass of 2005
Certifications & Licensure
OH State Medical License 2008 - 2026
MN State Medical License 2006 - 2008
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012, 2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma Start of enrollment: 2014 Mar 26
- IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia Start of enrollment: 2012 Jan 01
- PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia Start of enrollment: 2012 May 21
Publications & Presentations
PubMed
- A Phase I Study of Combination Duvelisib and Nivolumab in Patients With Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma, and Richter Transformation.Aseel Alsouqi, Ying Huang, Beth Christian, John Reneau, Seema A Bhat
European Journal of Haematology. 2026-03-01 - Clinical characteristics associated with terminal methotrexate clearance in patients with non-Hodgkin lymphomas receiving high-dose methotrexate.Zachary J Arnold, Jordan Lundberg, Tracy Wiczer, Demond Handley, David Bond
Journal of Oncology Pharmacy Practice. 2026-02-04 - Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Marginal Zone Lymphoma: Phase 1/2 BRUIN Study.Krish Patel, Julie M Vose, Sunita D Nasta, Jennifer R Brown, Kami J Maddocks
Blood Advances. 2026-01-16
Journal Articles
- Update on Mantle Cell LymphomaKami Maddocks, MD, Blood
Abstracts/Posters
- T-Cell Clonal Expansion and Activation Associated with Durable Clinical Response to Dual BTK and CDK4/6 Inhibitor Therapy in Mantle Cell LymphomaKami J. Maddocks, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Outcome of Autologous Stem Cell Transplantation Following PD-(L)1 Based Salvage Therapy for Multiply Relapsed Patients with Classic Hodgkin LymphomaKami J. Maddocks, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of...Kami J. Maddocks, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Lectures
- Emerging Paradigms to Address Unmet Needs in Relapsed/Refractory DLBCL61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Update of the single-arm phase II L-MIND study of MOR208 + lenalidomide (LEN) in relapsed/refractory diffuse large B-cell lymphoma (R-R DLBCL): Response rates in patie...2019 ASCO Annual Meeting - 6/1/2019
- Single-Arm Phase II Study of MOR208 Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: L-Mind2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Conference MDAngle: ASH 2025December 4th, 2025- Anticipated Immunotherapy Updates in Follicular LymphomaDecember 4th, 2025
- Tafasitamab Regimen Improves PFS in Relapsed/Refractory Follicular LymphomaJanuary 9th, 2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
